Data Insights

By Company Name

By Disease Name

By Drug Name

By Themes

Showing 4 results out of 4

Company Profiles

Access comprehensive reports covering all the major players in the pharmaceutical industry

Gain a competitive edge
Enhance your sales strategy
Get forward-looking insights
Support your decision making

Buy Now

Data Insights

Milvexian by Bristol-Myers Squibb for Acute Coronary Syndrome: Likelihood of Approval

Milvexian is under clinical development by Bristol-Myers Squibb and currently in Phase III for Acute Coronary Syndrome. According to GlobalData,...

Data Insights

Milvexian by Bristol-Myers Squibb for Venous Thromboembolism: Likelihood of Approval

Milvexian is under clinical development by Bristol-Myers Squibb and currently in Phase II for Venous Thromboembolism. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Milvexian in Venous Thromboembolism

Data Insights

Milvexian by Bristol-Myers Squibb for Atrial Flutter: Likelihood of Approval

Milvexian is under clinical development by Bristol-Myers Squibb and currently in Phase III for Atrial Flutter. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Milvexian in Atrial Flutter

Data Insights

Risk adjusted net present value: What is the current valuation of Bristol-Myers Squibb's Milvexian?

Milvexian is a small molecule commercialized by Bristol-Myers Squibb, with a leading Phase III program in Atrial Flutter. According to...

Net Present Value Model: Bristol-Myers Squibb Co's Milvexian

Sections

Sections

Sections

Sections

Sections

Company Profiles

Milvexian by Bristol-Myers Squibb for Acute Coronary Syndrome: Likelihood of Approval

Milvexian by Bristol-Myers Squibb for Venous Thromboembolism: Likelihood of Approval

Milvexian by Bristol-Myers Squibb for Atrial Flutter: Likelihood of Approval

Risk adjusted net present value: What is the current valuation of Bristol-Myers Squibb's Milvexian?